Search General Info
Search Education
Search Partnering Companies

Tai-Wei Ly

TaiPei, Taiwan
Dr. Ly has been involved in the drug development field since obtaining his doctorate from the University of Alberta followed by a post-doctoral tenure at Academia Sinica in Taiwan and is a prolific drug hunter as evidenced by his numerous publications and patents in the area. Dr. Ly began his career at Bayer’s research center in Kyoto (2002-2005) and then moved to the US to head up the chemistry efforts at Actimis (2005-2008) then Axikin (2008-2017) upon successfully navigating a structured buyout of Actimis by Boehringer Ingelheim. Upon closure of Axikin in 2017, Dr. Ly and his colleague Dr. Kevin Bacon formed SMA Therapeutics with assets from Axikin. Most recently, Dr. Ly joined TaiGen as their Director of Medicinal Chemistry with responsibilities of managing the chemistry efforts of the company as well as leading the early discovery efforts of TaiGen to ensure a continued and robust R&D pipeline that is relevant to current pharmaceutical needs for the betterment of patients.
Speaking In
[On Demand]
TaiGen focuses in the research and development of NCEs. TaiGen’s pipeline includes best-in-class…